-
According to a recent note by analyst James Reddoch of Friedman, Billings, Ramsey, an injunction hearing related to the molecule is scheduled for Jan. 30.
FORBES: Magazine Article
-
But James Reddoch at Friedman, Billings, Ramsey has written notes to investors saying that Reclast is, in fact pretty good--and that its efficacy will be hard to beat.
FORBES: Amgen's Next Opponents
-
Fifth Third Bancorp gets the thumbs-down from Bradley Vander Ploeg at Raymond James and Gary Townsend at Friedman Billings Ramsey.
FORBES: When Picky Analysts Pick
-
James Reddoch, an analyst Friedman, Billings, Ramsey, used prescription data from NDC Health to forecast the performance of biotech companies that he covers.
FORBES: Two Picks In Biotech Ahead Of Earnings
-
But the number of patients getting the medicine could double, according to a research note from James Reddoch, biotech analyst at Friedman, Billings, Ramsey.
FORBES